The Efficacy and Safety of Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer: A Prospective Clinical Study.
PD-1/L1 blockade
advanced biliary tract cancer
apatinib
camrelizumab (SHR-1210)
cholangiocarcinoma
combination therapy
immunotherapy
target therapy
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
28
12
2020
accepted:
18
03
2021
entrez:
29
4
2021
pubmed:
30
4
2021
medline:
30
4
2021
Statut:
epublish
Résumé
PD-1/L1 inhibitor-based immunotherapy is currently under investigation in biliary tract cancer (BTC). Apatinib combined with camrelizumab has achieved promising results in various tumor types. The aim of this study was to assess the safety and efficacy of apatinib plus camrelizumab for advanced biliary tract cancer patients who have received previously treatments. This prospective, non-randomized, open-label trial was conducted at Peking Union Medical College Hospital (PUMCH). All included patients received apatinib orally at 250 mg per a day and camrelizumab intravenously at 200 mg every three weeks until disease progression or intolerable toxicity occurred. Efficacy was evaluated based on the Response Evaluation Criteria in Solid Tumors RECIST Version 1.1 (RECIST 1.1). Adverse events (AEs) were assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE version 4.0). A total of 22 patients were consecutively enrolled from 1st December, 2018 until 1st August, 2020. Among 21 patients for whom we could conduct efficacy evaluations, no patients achieved a complete response (CR), 4 patients (19%) achieved partial response (PR), and 11 patients had stable disease with a disease control rate of 71.4%. The median overall survival was 13.1 months (95% CI, 8.1-18.2), and the median progression-free survival was 4.4 months (95% CI, 2.4-6.3). All patients experienced treatment related AEs, and grade 3 or 4 AEs occurred in 14 (63.6%) of 22 patients. No treatment related deaths were observed. This is the first report focusing on the efficacy and safety of camrelizumab plus apatinib in pretreated biliary tract cancer patients. The finding suggests this regimen has favorable therapeutic effects with relatively manageable toxicity. Further trials with a control arm are required to investigate. identifier NCT04642664.
Sections du résumé
BACKGROUND
BACKGROUND
PD-1/L1 inhibitor-based immunotherapy is currently under investigation in biliary tract cancer (BTC). Apatinib combined with camrelizumab has achieved promising results in various tumor types. The aim of this study was to assess the safety and efficacy of apatinib plus camrelizumab for advanced biliary tract cancer patients who have received previously treatments.
METHODS
METHODS
This prospective, non-randomized, open-label trial was conducted at Peking Union Medical College Hospital (PUMCH). All included patients received apatinib orally at 250 mg per a day and camrelizumab intravenously at 200 mg every three weeks until disease progression or intolerable toxicity occurred. Efficacy was evaluated based on the Response Evaluation Criteria in Solid Tumors RECIST Version 1.1 (RECIST 1.1). Adverse events (AEs) were assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE version 4.0).
RESULTS
RESULTS
A total of 22 patients were consecutively enrolled from 1st December, 2018 until 1st August, 2020. Among 21 patients for whom we could conduct efficacy evaluations, no patients achieved a complete response (CR), 4 patients (19%) achieved partial response (PR), and 11 patients had stable disease with a disease control rate of 71.4%. The median overall survival was 13.1 months (95% CI, 8.1-18.2), and the median progression-free survival was 4.4 months (95% CI, 2.4-6.3). All patients experienced treatment related AEs, and grade 3 or 4 AEs occurred in 14 (63.6%) of 22 patients. No treatment related deaths were observed.
CONCLUSIONS
CONCLUSIONS
This is the first report focusing on the efficacy and safety of camrelizumab plus apatinib in pretreated biliary tract cancer patients. The finding suggests this regimen has favorable therapeutic effects with relatively manageable toxicity. Further trials with a control arm are required to investigate.
CLINICAL TRIAL REGISTRATION
BACKGROUND
identifier NCT04642664.
Identifiants
pubmed: 33912461
doi: 10.3389/fonc.2021.646979
pmc: PMC8071846
doi:
Banques de données
ClinicalTrials.gov
['NCT04642664']
Types de publication
Journal Article
Langues
eng
Pagination
646979Informations de copyright
Copyright © 2021 Wang, Yang, Long, Lin, Mao, Xie, Wang, Wang, Xun, Bai, Yang, Guan, Pan, Seery, Sang and Zhao.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Lancet. 2014 Jun 21;383(9935):2168-79
pubmed: 24581682
Lancet. 2017 Jun 24;389(10088):2492-2502
pubmed: 28434648
Lancet Oncol. 2020 Apr;21(4):571-580
pubmed: 32112738
Curr Probl Cancer. 2018 Jan - Feb;42(1):49-58
pubmed: 29501212
JAMA Oncol. 2020 Jun 1;6(6):888-894
pubmed: 32352498
Br J Surg. 2017 Feb;104(3):267-277
pubmed: 28052308
Cancer Treat Rev. 2020 Jun;86:101998
pubmed: 32203843
Int J Cancer. 2020 Oct 15;147(8):2190-2198
pubmed: 32359091
Drugs. 2018 May;78(7):747-758
pubmed: 29663291
J Immunother Cancer. 2020 May;8(1):
pubmed: 32376724
Clin Cancer Res. 2021 Feb 15;27(4):1003-1011
pubmed: 33087333
Lancet Oncol. 2020 Jan;21(1):e29-e41
pubmed: 31908303
J Hepatol. 2014 Jun;60(6):1268-89
pubmed: 24681130
Hepatology. 2021 Jan;73 Suppl 1:75-85
pubmed: 32500550
J Hepatol. 2019 Jan;70(1):151-171
pubmed: 30266282
Neoplasma. 2020 Jul;67(4):715-723
pubmed: 32266817
Nat Rev Clin Oncol. 2018 Feb;15(2):95-111
pubmed: 28994423
J Hematol Oncol. 2019 Apr 24;12(1):42
pubmed: 31014381
Oncogene. 2013 Oct 10;32(41):4861-70
pubmed: 23318457
Cancer Manag Res. 2020 Jul 03;12:5345-5351
pubmed: 32753952
Cancer Immunol Immunother. 2019 Sep;68(9):1467-1477
pubmed: 31451841
J Immunother Cancer. 2020 May;8(1):
pubmed: 32448804
Hepatology. 2020 Sep;72(3):965-981
pubmed: 31875970
Semin Liver Dis. 2004 May;24(2):139-54
pubmed: 15192787
Histopathology. 2017 Sep;71(3):383-392
pubmed: 28419539
Lancet Gastroenterol Hepatol. 2019 Aug;4(8):575-577
pubmed: 31109809
Oncotarget. 2017 Apr 11;8(15):24644-24651
pubmed: 28445951
J Cancer. 2018 Jul 16;9(16):2773-2777
pubmed: 30123344
Hepatobiliary Surg Nutr. 2020 Aug;9(4):414-424
pubmed: 32832493
N Engl J Med. 2010 Apr 8;362(14):1273-81
pubmed: 20375404
Lancet Gastroenterol Hepatol. 2019 Aug;4(8):611-621
pubmed: 31109808